Unlocking the Potential of LOC102724642: A Drug Target and Biomarker for Anaphase-Promoting Complex Subunit 1-Like

Unlocking the Potential of LOC102724642: A Drug Target and Biomarker for Anaphase-Promoting Complex Subunit 1-Like

The anaphase-promoting complex (APC) is a protein complex that plays a crucial role in the regulation of cell division during the G1 phase of the cell cycle. Subunits of the APC have been implicated in various cellular processes, including the control of gene expression, DNA replication, and chromatin remodeling. One of the subunits that has received particular attention is LOC102724642, anaphase-promoting complex subunit 1-like.

In this article, we will explore the potential of LOC102724642 as a drug target and biomarker for APC-related diseases. We will discuss the current state of research on LOC102724642, its potential therapeutic applications, and the challenges and opportunities in the field.

Current Research and Theoretical Perspectives

LOC102724642, also known as p21, is a 21-kDa protein that is part of the APC subunit 1. As mentioned earlier, the APC is responsible for regulating cell division during the G1 phase by ensuring that the cell prepares for cell division by replicating its DNA, organizing its chromatin, and ensuring the stability of its chromosomes.

Studies have shown that LOC102724642 plays a critical role in regulating the growth and differentiation of various cell types. For example, LOC102724642 has been shown to promote the growth of human embryonic stem cells (ESCs) and to inhibit their differentiation into teratogenic blastocysts.

In addition, LOC102724642 has also been shown to play a role in the regulation of cell cycle progression and the association with various diseases, including cancer. For example, LOC102724642 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers.

Despite these promising findings, the full potential of LOC102724642 as a drug target or biomarker is not yet fully understood. There are several challenges that need to be addressed before LOC102724642 can be exploited for therapeutic applications.

One of the major challenges is the lack of understanding of the molecular mechanisms underlying the function of LOC102724642. While several studies have demonstrated the critical role of LOC102724642 in regulating cell cycle progression and the association with various diseases, more research is needed to understand its underlying molecular mechanisms.

Another challenge is the difficulty of expressing and purifying LOC102724642. While several genetic modifications have been used to express LOC102724642, the production of high levels of the protein remains a challenge. Additionally, the lack of recombinant expression vectors limits the scope of LOC102724642 research.

Theme: LOC102724642 as a Potential Drug Target

LOC102724642 has the potential to serve as a drug target due to its unique functions in the regulation of cell cycle progression and the association with various diseases. One of the potential therapeutic approaches for LOC102724642 is to target its activity with small molecules or antibodies that can modulate its activity.

For instance, LOC102724642 has been shown to be a potent inhibitor of the

Protein Name: Anaphase-promoting Complex Subunit 1-like

The "LOC102724642 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC102724642 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC102724653 | LOC102724682 | LOC102724684 | LOC102724719 | LOC102724748 | LOC102724761 | LOC102724768 | LOC102724778 | LOC102724785 | LOC102724786 | LOC102724790 | LOC102724802 | LOC102724808 | LOC102724849 | LOC102724889 | LOC102724900 | LOC102724929 | LOC102724934 | LOC102724945 | LOC102724948 | LOC102724968 | LOC102724977 | LOC102725019 | LOC102725030 | LOC102725038 | LOC102725065 | LOC102725112 | LOC102725148 | LOC102725159 | LOC102725238 | LOC103171574 | LOC104054148 | LOC105369160 | LOC105369165 | LOC105369166 | LOC105369167 | LOC105369194 | LOC105369197 | LOC105369209 | LOC105369212 | LOC105369213 | LOC105369250 | LOC105369302 | LOC105369308 | LOC105369309 | LOC105369312 | LOC105369315 | LOC105369325 | LOC105369326 | LOC105369366 | LOC105369367 | LOC105369368 | LOC105369380 | LOC105369384 | LOC105369388 | LOC105369391 | LOC105369395 | LOC105369401 | LOC105369410 | LOC105369441 | LOC105369455 | LOC105369456 | LOC105369464 | LOC105369501 | LOC105369506 | LOC105369513 | LOC105369530 | LOC105369531 | LOC105369566 | LOC105369568 | LOC105369572 | LOC105369574 | LOC105369603 | LOC105369612 | LOC105369614 | LOC105369617 | LOC105369623 | LOC105369625 | LOC105369628 | LOC105369639 | LOC105369645 | LOC105369655 | LOC105369663 | LOC105369689 | LOC105369698 | LOC105369705 | LOC105369709 | LOC105369710 | LOC105369732 | LOC105369735 | LOC105369736 | LOC105369743 | LOC105369749 | LOC105369750 | LOC105369761 | LOC105369765 | LOC105369772 | LOC105369775 | LOC105369777 | LOC105369780